This study is currently not recruiting participants.

A Randomized Controlled Open-Label Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer

Evaluation of Safety and Effectiveness of Investigational Medication at Different Doses

Not Recruiting
18 years - 100 years
Female
Phase N/A

Brief description of study.

The purpose of the study is to evaluate the safety, tolerability and effectiveness of SGI-110 and any potential benefits at different doses.

Detailed description of study

The purpose of the study is to evaluate the safety, tolerability and effectiveness of SGI-110 and any potential benefits at different doses.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Ovarian Cancer
  • Age: 18 years - 100 years
  • Gender: Female

The purpose of this study is to investigate the safety, tolerability, and effectiveness of an investigational medication at various doses. This study aims to understand how the medication works in the body and to identify any potential side effects.

Participants in the study will receive different doses of the investigational medication. Their health will be closely monitored to assess how well they tolerate the medication and to observe any changes in their condition.

  • Who can participate: Participants must be adults aged 18-65 who meet specific health criteria. Key eligibility factors include no history of severe allergic reactions and no current participation in other clinical trials.
  • Study details: Participants will be given different doses of an investigational medication and their health will be monitored. A placebo may be used, which is an inactive substance that looks like the investigational medication but does not contain any medicine.
Updated on 19 Feb 2024. Study ID: 1210009920

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team